J Peter Cegielski1, Pei-Chun Chan2,3, Zhiyi Lan4, Zarir F Udwadia5, Piret Viiklepp6, Jae-Joon Yim7, Dick Menzies4. 1. Division of Tuberculosis Elimination, Centers for Disease Control and Prevention, Atlanta, Georgia, USA. 2. Division of Chronic Infectious Diseases, Taiwan Centers for Disease Control, Taipei City, Taiwan. 3. Institute of Epidemiology and Preventive Medicine, College of Public Health, National Taiwan University, Taipei City, Taiwan. 4. Montreal Chest Institute and McGill International Tuberculosis Centre, Montreal, Quebec, Canada. 5. PD Hinduja National Hospital and Medical Research Institute, Mumbai, India. 6. Estonian Tuberculosis Registry, National Institute for Health Development, Tallinn, Estonia. 7. Division of Pulmonary and Critical Medicine, Department of Internal Medicine, Seoul National University College of Medicine, Seoul, South Korea.
Abstract
BACKGROUND: As new drugs are developed for multidrug-resistant tuberculosis (MDR-TB), the role of currently used drugs must be reevaluated. METHODS: We combined individual-level data on patients with pulmonary MDR-TB published during 2009-2016 from 25 countries. We compared patients receiving each of the injectable drugs and those receiving no injectable drugs. Analyses were based on patients whose isolates were susceptible to the drug they received. Using random-effects logistic regression with propensity score matching, we estimated the effect of each agent in terms of standardized treatment outcomes. RESULTS: More patients received kanamycin (n = 4330) and capreomycin (n = 2401) than amikacin (n = 2275) or streptomycin (n = 1554), opposite to their apparent effectiveness. Compared with kanamycin, amikacin was associated with 6 more cures per 100 patients (95% confidence interval [CI], 4-8), while streptomycin was associated with 7 (95% CI, 5-8) more cures and 5 (95% CI, 4-7) fewer deaths per 100 patients. Compared with capreomycin, amikacin was associated with 9 (95% CI, 6-11) more cures and 5 (95% CI, 2-8) fewer deaths per 100 patients, while streptomycin was associated with 10 (95% CI, 8-13) more cures and 10 (95% CI, 7-12) fewer deaths per 100 patients treated. In contrast to amikacin and streptomycin, patients treated with kanamycin or capreomycin did not fare better than patients treated with no injectable drugs. CONCLUSIONS: When aminoglycosides are used to treat MDR-TB and drug susceptibility test results support their use, streptomycin and amikacin, not kanamycin or capreomycin, are the drugs of choice. Published by Oxford University Press for the Infectious Diseases Society of America 2020.
BACKGROUND: As new drugs are developed for multidrug-resistant tuberculosis (MDR-TB), the role of currently used drugs must be reevaluated. METHODS: We combined individual-level data on patients with pulmonary MDR-TB published during 2009-2016 from 25 countries. We compared patients receiving each of the injectable drugs and those receiving no injectable drugs. Analyses were based on patients whose isolates were susceptible to the drug they received. Using random-effects logistic regression with propensity score matching, we estimated the effect of each agent in terms of standardized treatment outcomes. RESULTS: More patients received kanamycin (n = 4330) and capreomycin (n = 2401) than amikacin (n = 2275) or streptomycin (n = 1554), opposite to their apparent effectiveness. Compared with kanamycin, amikacin was associated with 6 more cures per 100 patients (95% confidence interval [CI], 4-8), while streptomycin was associated with 7 (95% CI, 5-8) more cures and 5 (95% CI, 4-7) fewer deaths per 100 patients. Compared with capreomycin, amikacin was associated with 9 (95% CI, 6-11) more cures and 5 (95% CI, 2-8) fewer deaths per 100 patients, while streptomycin was associated with 10 (95% CI, 8-13) more cures and 10 (95% CI, 7-12) fewer deaths per 100 patients treated. In contrast to amikacin and streptomycin, patients treated with kanamycin or capreomycin did not fare better than patients treated with no injectable drugs. CONCLUSIONS: When aminoglycosides are used to treat MDR-TB and drug susceptibility test results support their use, streptomycin and amikacin, not kanamycin or capreomycin, are the drugs of choice. Published by Oxford University Press for the Infectious Diseases Society of America 2020.
Authors: Payam Nahid; Sundari R Mase; Giovanni Battista Migliori; Giovanni Sotgiu; Graham H Bothamley; Jan L Brozek; Adithya Cattamanchi; J Peter Cegielski; Lisa Chen; Charles L Daley; Tracy L Dalton; Raquel Duarte; Federica Fregonese; C Robert Horsburgh; Faiz Ahmad Khan; Fayez Kheir; Zhiyi Lan; Alfred Lardizabal; Michael Lauzardo; Joan M Mangan; Suzanne M Marks; Lindsay McKenna; Dick Menzies; Carole D Mitnick; Diana M Nilsen; Farah Parvez; Charles A Peloquin; Ann Raftery; H Simon Schaaf; Neha S Shah; Jeffrey R Starke; John W Wilson; Jonathan M Wortham; Terence Chorba; Barbara Seaworth Journal: Am J Respir Crit Care Med Date: 2019-11-15 Impact factor: 21.405
Authors: Dennis Falzon; Neel Gandhi; Giovanni B Migliori; Giovanni Sotgiu; Helen S Cox; Timothy H Holtz; Maria-Graciela Hollm-Delgado; Salmaan Keshavjee; Kathryn DeRiemer; Rosella Centis; Lia D'Ambrosio; Christoph G Lange; Melissa Bauer; Dick Menzies Journal: Eur Respir J Date: 2012-10-25 Impact factor: 16.671
Authors: J Peter Cegielski; Ekaterina Kurbatova; Martie van der Walt; Jeannette Brand; Julia Ershova; Thelma Tupasi; Janice Campos Caoili; Tracy Dalton; Carmen Contreras; Martin Yagui; Jaime Bayona; Charlotte Kvasnovsky; Vaira Leimane; Liga Kuksa; Michael P Chen; Laura E Via; Soo Hee Hwang; Melanie Wolfgang; Grigory V Volchenkov; Tatiana Somova; Sarah E Smith; Somsak Akksilp; Wanpen Wattanaamornkiet; Hee Jin Kim; Chang-Ki Kim; Boris Y Kazennyy; Tatiana Khorosheva; Kai Kliiman; Piret Viiklepp; Ruwen Jou; Angela Song-En Huang; Irina A Vasilyeva; Olga V Demikhova; Joey Lancaster; Ronel Odendaal; Lois Diem; Therese C Perez; Tarcela Gler; Kathrine Tan; Cesar Bonilla; Oswaldo Jave; Luis Asencios; Gloria Yale; Carmen Suarez; Allison Taylor Walker; Inga Norvaisha; Girts Skenders; Ingrida Sture; Vija Riekstina; Andra Cirule; Erika Sigman; Sang-Nae Cho; Ying Cai; Seokyong Eum; Jongseok Lee; Seungkyu Park; Doosoo Jeon; Isdore C Shamputa; Beverly Metchock; Tatiana Kuznetsova; Rattanawadee Akksilp; Wanlaya Sitti; Jirapan Inyapong; Elena V Kiryanova; Irina Degtyareva; Evgenia S Nemtsova; Klavdia Levina; Manfred Danilovits; Tiina Kummik; Yung-Chao Lei; Wei-Lun Huang; Vladislav V Erokhin; Larisa N Chernousova; Sofia N Andreevskaya; Elena E Larionova; Tatyana G Smirnova Journal: Clin Infect Dis Date: 2015-10-27 Impact factor: 9.079
Authors: Shama D Ahuja; David Ashkin; Monika Avendano; Rita Banerjee; Melissa Bauer; Jamie N Bayona; Mercedes C Becerra; Andrea Benedetti; Marcos Burgos; Rosella Centis; Eward D Chan; Chen-Yuan Chiang; Helen Cox; Lia D'Ambrosio; Kathy DeRiemer; Nguyen Huy Dung; Donald Enarson; Dennis Falzon; Katherine Flanagan; Jennifer Flood; Maria L Garcia-Garcia; Neel Gandhi; Reuben M Granich; Maria G Hollm-Delgado; Timothy H Holtz; Michael D Iseman; Leah G Jarlsberg; Salmaan Keshavjee; Hye-Ryoun Kim; Won-Jung Koh; Joey Lancaster; Christophe Lange; Wiel C M de Lange; Vaira Leimane; Chi Chiu Leung; Jiehui Li; Dick Menzies; Giovanni B Migliori; Sergey P Mishustin; Carole D Mitnick; Masa Narita; Philly O'Riordan; Madhukar Pai; Domingo Palmero; Seung-kyu Park; Geoffrey Pasvol; Jose Peña; Carlos Pérez-Guzmán; Maria I D Quelapio; Alfredo Ponce-de-Leon; Vija Riekstina; Jerome Robert; Sarah Royce; H Simon Schaaf; Kwonjune J Seung; Lena Shah; Tae Sun Shim; Sonya S Shin; Yuji Shiraishi; José Sifuentes-Osornio; Giovanni Sotgiu; Matthew J Strand; Payam Tabarsi; Thelma E Tupasi; Robert van Altena; Martie Van der Walt; Tjip S Van der Werf; Mario H Vargas; Pirett Viiklepp; Janice Westenhouse; Wing Wai Yew; Jae-Joon Yim Journal: PLoS Med Date: 2012-08-28 Impact factor: 11.069